Comparative Pharmacology
Head-to-head clinical analysis: RECORLEV versus TRIALODINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RECORLEV versus TRIALODINE.
RECORLEV vs TRIALODINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RECORLEV (levoketoconazole) is an orally administered corticosteroid biosynthesis inhibitor that suppresses cortisol production by inhibiting adrenal and gonadal steroidogenic enzymes, particularly CYP17A1 (17α-hydroxylase and 17,20-lyase) and CYP11B1 (11β-hydroxylase). It also weakly inhibits CYP3A4 and other CYP enzymes.
TRIALODINE is a selective serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that potentiates the effects of serotonin, norepinephrine, and dopamine by blocking their reuptake at presynaptic neurons.
150 mg orally twice daily with a high-fat meal.
50–100 mg orally twice daily; maximum 200 mg/day.
None Documented
None Documented
18 hours; prolonged in renal impairment (up to 45 hours in CrCl <30 mL/min)
Terminal elimination half-life is 6-8 hours in healthy adults; prolongs to 12-15 hours in moderate renal impairment (CrCl 30-50 mL/min).
Renal: 85% as unchanged drug; Fecal: 10% as metabolites
Renal excretion accounts for 70-80% of clearance, primarily as unchanged drug. Biliary/fecal elimination constitutes 15-20%, with the remainder as minor metabolites.
Category C
Category C
Thyroid Hormone
Thyroid Hormone